Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
Cell Line, Tumor
Chondroitin Sulfate Proteoglycans
/ genetics
Disease Progression
Down-Regulation
Drug Resistance, Neoplasm
Humans
MAP Kinase Kinase Kinase 4
/ antagonists & inhibitors
Melanoma
/ drug therapy
Membrane Proteins
/ genetics
Mutation
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
RNA, Messenger
/ genetics
melanoma
CSPG4
BRAF‑mutated melanoma
MAPK pathway
drug resistance
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
08
10
2020
accepted:
23
12
2020
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
Chondroitin sulfate proteoglycan 4 (CSPG4) is a multifunctional transmembrane proteoglycan involved in spreading, migration and invasion of melanoma. In addition to the activating BRAF V600E mutation, CSPG4 was shown to promote MAPK signaling by mediating the growth‑factor induced activation of receptor tyrosine kinases. However, it remains elusive which factors regulate CSPG4 expression. Therefore, the aim of the present study was to examine whether BRAF and MEK inhibitors have an effect on the expression of CSPG4. We exposed a panel of BRAF‑mutant CSPG4‑positive or ‑negative melanoma cell lines to BRAF and MEK inhibitors. Protein levels of CSPG4 were analyzed by flow cytometry (FACS), immunofluorescence microscopy (IF), and western blotting.
Identifiants
pubmed: 33649790
doi: 10.3892/or.2021.7965
pmc: PMC7876987
pii: 14
doi:
pii:
Substances chimiques
CSPG4 protein, human
0
Chondroitin Sulfate Proteoglycans
0
Membrane Proteins
0
Protein Kinase Inhibitors
0
RNA, Messenger
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
MAP Kinase Kinase Kinase 4
EC 2.7.11.25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 2009 Oct 1;69(19):7538-47
pubmed: 19738072
Oncogene. 2006 May 11;25(20):2873-84
pubmed: 16407841
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Int J Cancer. 2005 Apr 10;114(3):426-32
pubmed: 15578703
Cell. 2010 May 14;141(4):583-94
pubmed: 20478252
J Cell Biol. 2004 Jun 21;165(6):881-91
pubmed: 15210734
Melanoma Res. 2019 Aug;29(4):365-375
pubmed: 31140988
Arch Biochem Biophys. 1983 Aug;225(1):370-83
pubmed: 6614928
J Cell Sci. 2001 Jun;114(Pt 12):2315-25
pubmed: 11493670
J Biol Chem. 1998 Mar 6;273(10):5955-62
pubmed: 9488735
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Nat Rev Cancer. 2019 Jul;19(7):377-391
pubmed: 31209265
Immunol Res. 2011 Aug;50(2-3):294-302
pubmed: 21717063
Cell Mol Biol Lett. 2017 Feb 28;22:4
pubmed: 28536635
Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57
pubmed: 22004131
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Expert Opin Ther Targets. 2015;19(10):1339-50
pubmed: 26190756
Oncotarget. 2015 May 20;6(14):12141-55
pubmed: 25987129
J Clin Oncol. 2011 Aug 1;29(22):3085-96
pubmed: 21383288
Biochem J. 2007 May 1;403(3):553-63
pubmed: 17217338
Oncogene. 2015 Aug 20;34(34):4545
pubmed: 25619837
J Transl Med. 2017 Jul 1;15(1):151
pubmed: 28668095
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Front Immunol. 2018 Jan 10;8:1911
pubmed: 29375561
Cancers (Basel). 2020 Apr 22;12(4):
pubmed: 32331483
Crit Rev Immunol. 2004;24(4):267-96
pubmed: 15588226
J Clin Oncol. 2014 Nov 20;32(33):3697-704
pubmed: 25287827
Int J Oncol. 2015 Jul;47(1):81-90
pubmed: 25997619
Adv Cancer Res. 2010;109:73-121
pubmed: 21070915
Oncotarget. 2014 Nov 15;5(21):10206-21
pubmed: 25344914
Oncotarget. 2017 Aug 3;8(44):78174-78192
pubmed: 29100459
J Cell Biol. 2007 Jul 2;178(1):155-65
pubmed: 17591920
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24
pubmed: 19251651
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nature. 2013 Feb 14;494(7436):251-5
pubmed: 23302800
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Biomedicines. 2017 Jun 28;5(3):
pubmed: 28657611